支原体耐药性变迁的研究

目的了解解放军174医院临床标本分离的支原体耐药性变迁，更好地指导临床合理用药。方法对2006-2008年就诊的可疑非淋菌性阴道炎（NGU）患者进行支原体的培养及药敏检测，抽取2006年230例，2007年和2008年各300例进行耐药变迁分析。结果交沙霉素（JOS）3年的耐药率均〈20％，喹诺酮类药物氧氟沙星（OFL）、左氧氟沙星（LEV）和司帕沙星（SPA）的耐药率呈较高水平。大环内酯类药物阿奇霉素（AZI）和罗红霉素（ROX）耐药率较高，尤其在解脲脲原体（Uu）＋人型支原体（Nh）混合感染中，喹诺酮类和大环内酯类的耐药率均在持续高水平状态，四环素类抗生素在混合感染中耐药率显著上升。结论强力霉素（DOX）、美满霉素（MIN）和交沙霉素（JOS）为治疗支原体的首选药物，但应定期监测支原体的耐药性变迁。

Study of Drug Resistance Evolution of Mycoplasma

[Objective]To investigate the drug resistance evolution of isolated strain of mycoplasma in No. 174 Hospital of PLA so as to well guide rational drug use in clinic.[Methods]Suspicious non-gonococcal vaginitis(NGU) patients during 2006-2008 were conducted mycoplasma cultivation and drug susceptibility test. 230 Cases in 2006 and each 300 cases in 2007 and 2008 were selected to conduct analysis of drug resistance evolution.[Results]The drug resistance rates of josamycin (JOS) was lower than 20% during the 3 years, and drug resistance to Quinolones, such as ofloxacin (OFL), levofloxacin (LEV) and sparfloxacin (SPA), was high. Macrolide antibiotics Azithromycin (AZI) and roxithromycin (ROX) had a high drug resistance rate, especially in the patients with Ureaplasma urealyticum (Uu) and Mycoplasma hominis (Mh) mixed infection, resistance rates of Quinolone and macrolide sustained at a high level, the drug resistance rates of tetracycline antibiotics increased significantly in treating mix infection.[Conclusion]The preferred drugs for treating mycoplasma were DOX, MIN and JOS, however, the drug resistance evolution should be monitored regularly.